<DOC>
	<DOCNO>NCT00430300</DOCNO>
	<brief_summary>Safety efficacy ( measured spirometry ) UK-432,097 administration test patient chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients diagnosis , least 6 month , moderate severe COPD ( GOLD ) meet criterion Stage IIIII disease Patients must smoke history least 10 packyears Patients must stable disease least 1 month prior screen . More 2 exacerbation COPD precede year History low respiratory tract infection significant disease instability month proceding screening time screen randomization . History presence respiratory failure , cor pulmonale right ventricular failure</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Dry Powder Inhalation</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Lung Function test</keyword>
</DOC>